Ascendis Pharma A/S (ASND)

135,40 +2,75 (+2,07%) Börsenschluss: 04:00PM EDT

Ascendis Pharma A/S

Tuborg Boulevard 12
Hellerup 2900
Denmark
45 70 22 22 44
https://ascendispharma.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 879

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Jan Moller Mikkelsen	President, CEO, Member of Executive Board & Executive Director	N/A	N/A	1960
Mr. Scott T. Smith	CFO, Executive VP & Member of Executive Board	N/A	N/A	1974
Ms. Lotte Sonderbjerg	Executive VP, Chief Administrative Officer & Member of the Executive Board	N/A	N/A	1961
Mr. Michael Wolff Jensen L.L.M.	Executive VP, Chief Legal Officer & Member of the Executive Board	N/A	N/A	1971
Mr. Mads Bodenhoff	Senior VP of Finance & Principal Accounting Officer	N/A	N/A	N/A
Mr. Timothy J. Lee	Senior Director of Investor Relations	N/A	N/A	N/A
Mr. Flemming Steen Jensen	Executive Vice President of Product Supply & Quality	N/A	N/A	1961
Dr. Kennett Sprogoe Ph.D.	Executive VP and Head of Research & Product Development	N/A	N/A	1979
Dr. Stina Singel M.D., Ph.D.	Executive VP & Head of Clinical Development for Oncology	N/A	N/A	1974
Mr. Joseph Kelly	Head of U.S. Commercial of Endocrinology	N/A	N/A	1969

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Corporate Governance

Ascendis Pharma A/Ss ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.